Surabgene Lomparvovec (ABBV-RGX-314), Surabgene Lomparvovec (ABBV-RGX-314)
M23-422
Phase 2 small_molecule active
Quick answer
Surabgene Lomparvovec (ABBV-RGX-314), Surabgene Lomparvovec (ABBV-RGX-314) for Neovascular age-related macular degeneration is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Neovascular age-related macular degeneration
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active